What is TheraBreath?
Founded in 1994, TheraBreath has evolved from a niche oral care provider into a comprehensive health solutions brand. The company specializes in a diverse portfolio of products addressing halitosis, periodontal health, teeth whitening, and xerostomia. By maintaining a commitment to gluten-free formulations and a satisfaction-guaranteed business model, TheraBreath has successfully bridged the gap between clinical efficacy and consumer accessibility. Its inclusion in the Inc 5000 list in 2021 serves as a testament to its operational excellence and strong brand equity within the retail pharmacy ecosystem, where it serves both individual consumers and commercial partners.
How much funding has TheraBreath raised?
TheraBreath has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in TheraBreath
PPP
Public-Private Partnership
What's next for TheraBreath?
With the infusion of $350K, TheraBreath is well-positioned to accelerate its growth strategy, likely focusing on deepening its penetration in international markets and expanding its digital-first retail presence. The company's focus on high-growth segments like preventative oral care suggests a strategic pivot toward long-term wellness integration. As it navigates the complexities of the late-stage lifecycle, the firm will likely prioritize supply chain optimization and the diversification of its product pipeline to maintain its competitive edge against both legacy oral care conglomerates and emerging direct-to-consumer health brands.
See full TheraBreath company page
